Ricardo Grieshaber-Bouyer
Professor – Clinical Systems Immunology Friedrich-Alexander- Universität Erlangen- Nürnberg
Seminars
Wednesday 25th March 2026
Panel Discussion: Walking the Therapeutic Tightrope Between Efficacy & Safety in B-Cell Targeted Therapies for Autoimmune Diseases vs Oncology
10:00 am
Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:
- Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
- Addressing the risks associated at various level of depletion such as elevated BAFF
- Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion
Tuesday 24th March 2026
Morning Session
9:00 am
Defining Immune Resetting: Translational Approaches to Profiling B-Cells to Understand the Depth of Depletion
Join this workshop to discuss how we measure the immune reset and to what depth must we deplete B-Cells:
- Clarifying the constitution of a true ‘immune reset’ following B-cell depletion therapy vs transient immunosuppression
- Discussing the restoration of the stable self-tolerant immune system
- Understanding optimal depletion targets to understand which populations must be depleted and to what extent to achieve a sustainable therapeutic effect
- Reflecting on the necessary therapeutic strategies needed to target long-lived plasma cells within the bone marrow
- Advancing B-cell profiling techniques such as single-cell RNA sequencing, flow, and mass cytometry, and adaptive immune receptor repertoire sequencing
- Discussing the effective definition of B-cell depletion through cellular and molecular biomarkers that correlate with depletion depth and sustained immune reset
Wednesday 25th March 2026
Fireside Chat: Effectively Operationalizing Clinical Trials in Immune Resetting Therapeutics
4:00 pm
- Securing Centre’s of Excellence with necessary oncology and rheumatology clinical expertise for patient screening lymphodepletion and toxicity management
- Addressing the competitive landscape around securing sites and managing site capacity that can risk delaying trial activation and delaying patient enrolment
- Improving patient enrolment practices through streamlining the patient journey, site education and increasing the centralization of trials to be more accessible
